Trial intelligence / Profile preview

Artesunate-mefloquine efficacy and safety in uncomplicated falciparum malaria in Thailand

ACTRN12611000521921Phase 4Not yet recruiting

Sponsor
Bureau of Vector Borne Diseases
Start
Jun 2011
Modality
Small Molecules
Countries
1
01

Overview

Phase 4, open-label, single-arm trial of artesunate, mefloquine and primaquine in Malaria, sponsored by Bureau of Vector Borne Diseases. Primary endpoint: WHO-classified treatment outcome. Planned start Jun 2011; status: not yet recruiting.

02

Drugs

artesunatemefloquineprimaquine
03

Conditions

Malaria

Beyond the preview

Go deeper on ACTRN12611000521921.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ACTRN12611000521921.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call